Haemonetics Corp. (NYSE:HAE) plans to lay off about 170 workers and close facilities in Phoenix and Chicago as it integrates its new, $61 million acquisition, GlobalMed Technologies (OTC:GLOB).
Haemonetics to lay off 170 in GlobalMed integration
Haemonetics
Haemonetics closes GlobalMed tender offer
Haemonetics Corp. (NYSE HAE) owns about 90 percent of GlobalMed Technologies Inc. this morning, after its extended tender offer for the California-based software provider expired at midnight March 31.
Nutter squirrels away $2.7 million from recent stock sales
Nearly a year after stepping down as CEO at Haemonetics Corp. (NYSE:HAE), Brad Nutter cashed in another bloc of his holding’s in the blood management firm.
Nutter exercised just more than 173,000 options to purchase Haemonetics stock granted in July 2006 under a long-term incentive program for top executives. The options were priced at $41.15 a share and he promptly the sold the stock for $57 each — a $15.85-per-share profit resulting in net proceeds of nearly $2.75 million.
Haemonetics licenses Alba Bioscience blood typing reagents
Haemonetics Corp. (NYSE:HAE) inked a deal with Quotient Biodiagnostics Group subsidiary Alba Bioscience Ltd. that gives it exclusive access to Alba’s portfolio of blood-typing reagents.
The Braintree, Mass.-based blood management products maker will use the reagents for the Arryx laser blood typing platform, which CEO Brian Concannon calls the entry point into a billion-dollar market.
Haemonetics extends GlobalMed offer
Haemonetics Corp. (NYSE:HAE) extended its offer for GlobalMed Technologies Inc. to give the California-based software provider time to settle a shareholders lawsuit filed to block the acquisition.
Braintree, Mass.-based Haemonetics issued a $1.22-per-share offer, worth about $60 million and set to expire tonight at midnight, for GlobalMed Feb. 1.
Haemonetics wins further 510(k) clearance for blood collection
The Food & Drug Administration expanded a 510(k) clearance for a Haemonetics Corp. (NYSE:HAE) device used to collect blood.
The Braintree, Mass.-based firm said the FDA expanded its clearance to use its Cymbal automated blood collection system for female blood donors who weigh at least 150 pounds and are 63 inches in height.
Haemonetics drops $60 million on GlobalMed, posts Q3 gains
Haemonetics Corp. (NYSE:HAE) is expanding its reach into hospital and blood center management, announcing a definitive agreement to pay $60 million for a California-based healthcare software company.
Company executives said the deal — the company’s fourth in less than a year — for GlobalMed Technologies Inc. should significantly expand Haemonetics’ offerings for blood-collection centers with little overlap of its existing business. The acquisition also should broaden Haemonetics’ presence in Europe and Asia, they said.
